Sherie Morrison, UCLA David Geffen School of Medicine, to Speak at ImmunoTx Summit

Monrovia, CA, November 30, 2016 --(PR.com)-- Sherie Morrison, Distinguished Professor at UCLA’s David Geffen School of Medicine, will give a presentation on “Antibody Fusions with Interferon for the Treatment of Malignancy” at GTCbio’s 9th Immunotherapeutics & Immunomonitoring Conference, which is happening on February 6-7, 2016 at the Hard Rock Hotel in San Diego, CA.

Type I interferons (IFN-alpha/IFN-beta) exhibit multiple potent anti-tumor properties. An attractive approach to improving efficacy while reducing toxicity is to deliver IFN to the site of the tumor by fusing it to an antibody specific for a tumor associated antigen (TAA). Dr. Morrison's lab found IFN fusion proteins to be effective therapeutics when targeted to TAAs on a number of different cancers.

Dr. Morrison is among the leading scientific and clinical experts from academia and industry to speak at the 9th Immunotherapeutics & Immunomonitoring Conference. New immunological concepts with clinically translational implications will be discussed, along with evaluations of novel drug targets and therapeutic approaches, the role of biomarkers in immunomonitoring, and the latest data on combinatorial treatments in the clinic.

This conference is also part of our larger ImmunoTx Summit, which consists of the following conferences:

9th Immunotherapeutics & Immunomonitoring Conference
5th Immunogenicity & Immunotoxicity Conference
15th Cytokines & Inflammation Conference

For more information, please visit website: https://www.gtcbio.com/conferences/immunotx-summit-agenda